S1 Appendix
TREND Statement Checklist - adapting the concepts of quiasi-experimental studies by the authors.

TREND Statement Checklist - Impact assessment of pharmaceutical care in the management of hypertension and coronary risk factors after discharge

| Paper Section/ Topic | Item No | Descriptor | Reported? | Pag |
|----------------------|---------|------------|-----------|-----|
| Title and Abstract   | 1       | Information on how unit were allocated to interventions |           | 1 - Impact assessment of pharmaceutical care in the management of hypertension and coronary risk over three years after discharge |
| Structured abstract recommended | | | | |
| Information on target population or study sample | | | | |
| Introduction         | 2       | Scientific background and explanation of rationale |           | 2-3 - We emphasize the importance of chronic diseases in the world, the high prevalence of hypertension, ineffective results for the control of blood pressure and called it to the results that the PC has achieved, and highlight the importance of showing these results after discharge, as our study |

1- The PC was performed in two basic units of the public health system in Ribeirão Preto-SP, Brazil, where the pharmacist followed up 104 patients.
Theories used in designing behavioral interventions

**Methods**

**Participants**

Eligibility criteria for participants, including criteria at different levels in recruitment/sampling plan (e.g., cities, clinics, subjects)

3 - Individuals diagnosed with SAH and in medical care for the disease, aged over 20 years, users of the health unit within the PC program, and those who used at least one antihypertensive medication were included in the program. The program excluded patients who could not continue the planning of pharmaceutical consultations, pregnant women and those who had some kind of diagnosed cognitive impairment.

4 - From August to November 2008 the patient was approached at the time of receipt of the drug in the health unit, and invited to participate in the PC program. If the patient met the inclusion criteria and did not meet any item in the exclusion criteria, they were invited to sign the Free and Informed Consent Terms, with guidance from the pharmacist of the program.

4 - From this moment the patient was included in the PC program. During 2009, from January to December, one pharmacist followed up 104 patients in this PC program. In 2013, data collection for this study was performed in order to gather the clinical and health care data of individuals monitored by PC. Thus, from January 2006 to December 2012 the data were collected through the patient record and the Hygiaweb® computerized system.

Method of recruitment (e.g., referral, self-selection), including the sampling method if a systematic sampling plan aimed.
was implemented

Recruitment setting

Settings and locations where the data were collected

Interventions

Details of the interventions intended for each study condition and how and when they were actually administered, specifically including:

- **Content**: what was given?

- **Delivery method**: how was the content given?

- **Unit of delivery**: how were the subjects grouped during delivery?

- **Deliverer**: who delivered the intervention?

- **Therefore, during 2009 each patient was scheduled to consult the pharmacist once a month during a year in the health units of study.**

4. Subsequent consultations followed the relevant activities of pharmacotherapeutic monitoring, considering blood pressure measurements and measures of cardiovascular risk, analysis of medicines and test results, health education with guidance on patient behavior regarding life habits, adherence to treatment, and if necessary interventions in pharmacotherapy.

- **Therefore, during 2009 each patient was scheduled to consult the pharmacist once a month during a year in the health units of study.**

3. This PC program was conducted by one pharmacist in two units of primary health of the PHS in Ribeirão Preto-SP, Brazil; 5- the pharmacist.
o Setting: where was the intervention delivered?

5- in the health units of study

4- was scheduled to consult the pharmacist once a month during a year

4- one year

4- one year

5- During all PC period, the pharmacist worked on health education through informative lectures, educational materials on health, and guidance during the consultations. Adherence to drug therapy was also worked on.

5- During all PC period, the pharmacist worked on health education through informative lectures, educational materials on health, and guidance during the consultations. Adherence to drug therapy was also worked on.

o Exposure quantity and duration: how many sessions or episodes or events were intended to be delivered? How long were they intended to last?

4- was scheduled to consult the pharmacist once a month during a year

Time span: how long was it intended to take to deliver the intervention to each unit?

4- one year

5- in the health units of study

4- one year

o Activities to increase compliance or adherence (e.g., incentives)

5- in the health units of study

4- was scheduled to consult the pharmacist once a month during a year

4- one year

Objectives

Specific objectives and hypotheses

7- Indicators to assess the impact of Pharmaceutical Care; under hypothesis that the results are maintained even three years after discharge

7- Indicators to assess the impact of Pharmaceutical Care; under hypothesis that the results are maintained even three years after discharge

Outcomes

Clearly defined primary and secondary outcome measures

7- The indicators were defined according to the clinical and care data, considering primary outcome, blood pressure, and secondary outcomes, plasma lipid levels, coronary risk and care.

7- The indicators were defined according to the clinical and care data, considering primary outcome, blood pressure, and secondary outcomes, plasma lipid levels, coronary risk and care.

Methods used to collect data and any methods used to enhance the quality of measurements

Information on validated instruments such as psychometric and biometric properties

4- Thus, from January 2006 to December 2012 the data were collected through the patient record and the Hygiaweb®, computerized system.

4- Thus, from January 2006 to December 2012 the data were collected through the patient record and the Hygiaweb®, computerized system.

Sample Size

How sample size was determined

6- Sample planning and sample of Pharmaceutical Care

6- Sample planning and sample of Pharmaceutical Care
| Assignment Method | 8 |
|-------------------|---|
| **Unit of assignment** (the unit being assigned to study condition, e.g., individual, group, community) | 8 – group - Importantly, the data were divided into three periods for analysis: from 2006 to 2008, defined as pre-PC; in 2009 defined as PC; from 2010 to 2012 defined as post-PC. |

| Blinding (masking) | 9 |
|--------------------|---|
| Whether or not participants, those administering the interventions, and those assessing the outcomes were blinded to study condition assignment; if so, statement regarding how the blinding was accomplished and how it was assessed. | No applied |

| Unit of Analysis | 10 |
|------------------|---|
| Description of the smallest unit that is being analyzed to assess | 7 - For the analysis of clinical indicators, the data were categorized as satisfactory; |
intervention effects (e.g., individual, group, or community)

If the unit of analysis differs from the unit of assignment, the analytical method used to account for this (e.g., adjusting the standard error estimates by the design effect or using multilevel analysis)

Statistical Methods

11

Statistical methods used to compare study groups for primary methods outcome(s), including complex methods of correlated data

Statistical methods used for additional analyses, such as a subgroup analyses and adjusted analysis

Methods for imputing missing data, if used

Statistical software or programs used

Method used to assign units to study conditions, including details of any restriction (e.g., blocking, stratification, minimization)

8-9 - The inferential statistical analysis was performed using Statistical Analysis System (SAS) version 9.2 and to develop the graphs statistical analysis GraphPad Prisma version 5 was used. For hypothesis testing a 5% significance level was considered. Importantly, the data were divided into three periods for analysis: from 2006 to 2008, defined as pre-PC; in 2009 defined as PC; from 2010 to 2012 defined as post-PC. The inferential statistic was based on paired data, this means relating to the data of the same individuals for analysis at different time points, because of this there were no potential confounders. Thus, for the clinical indicators the Cochran Q test was performed to compare variables of categorical type. ANOVA for medication and coronary risk and Friedman for consultation.

Pg 7 - Figure 1.

and unsatisfactory. Pg 6 and 8 – Coronary risk – Framingham scale; Care indicators – drugs in mg/ patient / years; and consultation: countable consultations.
Inclusion of aspects employed to help minimize potential bias induced due to non-randomization (e.g., matching)

Results
Participant flow

Flow of participants through each stage of the study: enrollment, assignment, allocation, and intervention exposure, follow-up, analysis (a diagram is strongly recommended)

- Enrollment: the numbers of participants screened for eligibility, found to be eligible or not eligible, declined to be enrolled, and enrolled in the study
- Assignment: the numbers of participants assigned to a study condition
- Allocation and intervention exposure: the number of participants assigned to each study condition and the number of participants who received each intervention

We believe we represent the flow of patients in Figure 1. We put on methods due justify the stratification of the sample size for each indicator analyzed and described this methodology. This option to put the methodology is justified by this study does not refer specifically to the intervention program, but the period after discharge. However, we discussed this in the discussion of the results.

The method used to select the sample was convenience sampling, whereby 191 patients were invited who were considered eligible in accordance with the inclusion criteria and 37 individuals were exclude because did not fulfill the eligibility criteria for this study;

Figure 1 – 104 patients, after before comparison.

whereby 191 patients were invited who were considered eligible, and 104 completed the follow-up. Figure 1.
Follow-up: the number of participants who completed the follow-up or did not complete the follow-up (i.e., lost to follow-up), by study condition

Analysis: the number of participants included in or excluded from the main analysis, by study condition

| Description of protocol deviations from study as planned, along with reasons | Recruitment | Dates defining the periods of recruitment and follow-up |
|-----------------------------------------------------------------------------|-------------|--------------------------------------------------------|
| Baseline Data                                                              | 14          | Baseline demographic and clinical characteristics of participants in each study condition |
| Baseline characteristics for each study condition relevant to specific disease prevention research |             | Pg 9 table 1. |

According to the sample size calculation for the dependent variable, the 57 patients who had the SBP and DBP variable analyzed in our study were representative to make inferences to the study population.

From this moment the patient was included in the PC program. During 2009, from January to December, one pharmacist followed up 104 patients in this PC program. In 2013, data collection for this study was performed in order to gather the clinical and health care data of individuals monitored by PC.

Pg 4 - Table 2.
Baseline comparisons of those lost to follow-up and those retained, overall and by study condition

Comparison between study population at baseline and target population of interest

Baseline equivalence  
Data on study group equivalence at baseline and statistical methods used to control for baseline differences

Numbers analyzed  
Number of participants (denominator) included in each analysis for each study condition, particularly when the denominators change for different outcomes; statement of the results in absolute numbers when feasible

Indication of whether the analysis strategy was “intention to treat” or, if not, description of how non-compliers were treated in the analyses

Outcomes and estimation  
For each primary and secondary outcome, a summary of results for each estimation study condition, and the estimated effect size and a confidence interval to indicate the precision

Not applied.

Pg 10 – 11 - Table 2; table 3 and figure 2 and 3.

Pg 10 – 11 - Table 2; table 3 and figure 2 and 3.

Pg 10 – 11 – table 2 and 3.

Pg 10 – 11 - Table 2; table 3 and figure 2 and 3.
Inclusion of null and negative findings

Inclusion of results from testing pre-specified causal pathways through which the intervention was intended to operate, if any

Ancillary analyses

18

Summary of other analyses performed, including subgroup or restricted analyses, indicating which are pre-specified or exploratory

Adverse events

19

Summary of all important adverse events or unintended effects in each study condition (including summary measures, effect size estimates, and confidence intervals)

DISCUSSION

Interpretation

20

Interpretation of the results, taking into account study hypotheses, sources of potential bias, imprecision of measures, multiplicative analyses, and other limitations or weaknesses of the study

Pg 10 - 11 - Table 2; LDL, HDL, TG; and table 3 – medication.

Pg 11 – Table 3; Post test bonferroni and Dunns.
Not applied.

Pg 11 – 14- We discussed the results of each indicator and compare with the literature, the limitations were explained in the last paragraph of the manuscript, and concluded by stating that there is a hypothesis generated, because this study is quasi-experimental.
Discussion of results taking into account the mechanism by which the intervention was intended to work (causal pathways) or alternative mechanisms or explanations

Discussion of the success of and barriers to implementing the intervention, fidelity of implementation

Discussion of research, programmatic, or policy implications

Pg 13 - PC addresses the individual as a whole in their biopsychosocial characteristics, involving health-education activities. Despite using pharmacotherapy in the planning of PC actions, PC is not restricted to the pharmacological effects. In this sense, non-pharmacological interventions and guidelines empowering the patient to their care are made, improving adherence and quality of life.

Pg 15 - is expected that these results help in the development of systematic reviews and methodological development of new studies evaluating this technology in health. Considering the optimization of outcomes by PC, which are also supported by other studies, it is intended that these results assist in the effective implementation of PC in the PHS, mainly in the collaboration of not only the immediate outcomes, but also for viewing the PC results after discharge of patients.

Pg 16 - To sum up, these results showed that PC is a professional practice able to be incorporated into the health services in order to contribute to the reduction of the risk of coronary heart disease and also to morbi-mortality from hypertension, under the hypothesis generated by this work that the results are maintained even three years after discharge.
Generalizability

Generalizability (external validity) of the trial findings, taking into account the study population, the characteristics of the intervention, length of follow-up, incentives, compliance rates, specific sites/settings involved in the study, and other contextual issues.

Overall Evidence

General interpretation of the results in the context of current evidence and current theory.

From: Des Jarlais, D. C., Lyles, C., Crepaz, N., & the Trend Group (2004). Improving the reporting quality of nonrandomized evaluations of behavioral and public health interventions: The TREND statement. American Journal of Public Health, 94, 361-366.